Epidemiological changes in hepatitis C virus genotypes in France: evidence in intravenous drug users.
about
Review article: HCV genotype 3 – the new treatment challengeHepatitis C virus infection epidemiology among people who inject drugs in Europe: a systematic review of data for scaling up treatment and preventionAnalysis of the 5' Noncoding Region versus the NS5b Region in Genotyping Hepatitis C Virus Isolates from Blood Donors in FranceImprovement of Hepatitis C Virus (HCV) Genotype Determination with the New Version of the INNO-LiPA HCV AssayUse of Sequence Analysis of the NS5B Region for Routine Genotyping of Hepatitis C Virus with Reference to C/E1 and 5' Untranslated Region SequencesHepatitis C virus genotypes distribution and transmission risk factors in Luxembourg from 1991 to 2006Origin of hepatitis C virus genotype 3 in Africa as estimated through an evolutionary analysis of the full-length genomes of nine subtypes, including the newly sequenced 3d and 3eA review of the evidence for the effectiveness of primary prevention interventions for hepatitis C among injecting drug users.Comparison of hepatitis C virus NS5b and 5' noncoding gene sequencing methods in a multicenter study.Temporal changes in HCV genotype distribution in three different high risk populations in San Francisco, CaliforniaIncreased prevalence of hepatitis C virus subtype 6a in China: a comparison between 2004-2007 and 2008-2011.Significant epidemiological changes in chronic hepatitis C infection: results of the nationwide HEPNET-GREECE cohort study.Distribution and predominance of genotype 3 in hepatitis C virus carriers in the province of kahramanmaras, Turkey.High prevalence of hepatitis C virus type 5 in central France evidenced by a prospective study from 1996 to 2002.Intravenous Drug Users Can Achieve a High Sustained Virological Response Rate: experience From Croatian Reference Center for Viral HepatitisChanging pattern of clinical epidemiology on hepatitis C virus infection in southwest china.Evaluation of the Abbott Real Time HCV genotype II assay for Hepatitis C virus genotyping.Injection drug use and the hepatitis C virus: considerations for a targeted treatment approach--the case study of Canada.Clinical Features and Outcomes of Patients With Genotype 3 Hepatitis C Virus Infection in Korea: A Retrospective Observational Study.HEPATITIS C VIRUS GENOTYPES IN INJECTING DRUG USERS FROM ROMANIA.Current approaches to HCV infection in current and former injection drug users.Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: A randomized phase III study (ALLY-3+).An overview about hepatitis C: a devastating virus.Prevalence and distribution of hepatitis C virus genotypes in Spain during the 2000-2015 period (the GEHEP 005 study).Usefulness of Dried Blood Spots (DBS) to perform hepatitis C virus genotyping in drug users in Senegal.Changes in hepatitis C virus genotype distribution in Japan.Factors to improve the management of hepatitis C in drug users: an observational study in an addiction centre.The hepatitis C virus genotype and subtype frequency in hepatitis C virus RNA-positive, hepatitis C virus antibody-negative blood donors identified in the nucleic acid test screening program in Poland.Changing of hepatitis C virus genotype patterns in France at the beginning of the third millenium: The GEMHEP GenoCII Study.Changes in epidemiological patterns of HCV infection and their impact on liver disease over the last 20 years in Greece.Molecular epidemiology of hepatitis C virus (HCV) in Greece: temporal trends in HCV genotype-specific incidence and molecular characterization of genotype 4 isolates.Identifying heterogeneity among injection drug users: a cluster analysis approach.Distribution of Hepatitis C virus genotypes among newly acquired HCV infections in British Columbia (2000-2013).
P2860
Q26864571-4EF4B3D9-8A48-4BAD-9487-12B0CA2E7A27Q27014761-CCC32837-E855-4C1F-A812-99DC4E43E621Q27473295-2C5411CD-933B-4A24-9180-FF41F42619D9Q27478358-17268237-3821-48DE-99A4-ACBDD2FC94B2Q27478359-37866BD0-80CB-4353-964C-937742F390A0Q27488500-6A29D883-40D2-41B6-844B-F08F9C04878BQ28655567-519B8729-BE01-4574-B52C-8A134AA0A01DQ33256564-3FE55FB8-AAA8-4041-83EE-342C96C6F220Q33825378-FB8B7AAF-1E6E-4606-B586-237A31F225D0Q33978978-9334DB38-7DB9-4D16-BC44-3C26C1D4C22DQ34459438-255B1C47-FFDA-48F7-9268-E06D9E6CFA45Q34976736-4F78A156-3101-4B2E-99EC-03A37E44531BQ35589848-6E7D0081-954D-4587-B4EF-2F51B458FB93Q35719045-DBF43927-B60F-4FF8-8E9B-3D79E87620EEQ35764220-E5FF55BD-02C1-4ACB-9DBD-77112B324668Q35920144-5E4EBFE1-6953-4A7E-9C68-31CBE94DBBDDQ36270128-A334E348-FFEC-4DCB-B0A4-46DBCF7438A6Q36272393-BB9A6490-DCBB-4C3A-86EA-76C309399DC8Q36581068-83E8E30F-AA94-4B46-BC21-4BBF5CEA253AQ36761081-506651B7-C9B7-478D-926E-650F257D5679Q37235530-0DEA0E6A-14D9-4FDF-B13D-48F74B8E4366Q37349005-7AB85C65-B5F0-4FAB-BA1B-087FCBC8BBB6Q37719516-26163C79-AD12-4097-9FEE-45636F0AC655Q38935930-985B176F-5C81-4693-9D3E-82B53B704D6AQ40857029-AB9E733C-990B-45B0-ADF8-A8ADDD1D0B92Q42225539-EDE006DE-6735-4F20-8706-FD4D431598A7Q42510746-9A4BBB65-E382-42A3-A40F-E62B4E635324Q42989340-7B7C512F-726C-4B8A-BF77-04C6A39E7442Q42993489-63A762F3-DC14-4259-B921-63E974AECE8DQ42994539-1DCA0494-0D43-4B46-BC8D-71C8750A40ACQ42997217-0F9C72F2-6474-40DD-8364-340DB470CA79Q51698391-C1D82737-5BB3-4B17-A2AC-2C2806A25155Q55331813-89E16B4D-1520-40E0-896B-97B36662C910
P2860
Epidemiological changes in hepatitis C virus genotypes in France: evidence in intravenous drug users.
description
2002 nî lūn-bûn
@nan
2002 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Epidemiological changes in hep ...... nce in intravenous drug users.
@ast
Epidemiological changes in hep ...... nce in intravenous drug users.
@en
type
label
Epidemiological changes in hep ...... nce in intravenous drug users.
@ast
Epidemiological changes in hep ...... nce in intravenous drug users.
@en
prefLabel
Epidemiological changes in hep ...... nce in intravenous drug users.
@ast
Epidemiological changes in hep ...... nce in intravenous drug users.
@en
P2093
P2860
P1476
Epidemiological changes in hep ...... nce in intravenous drug users.
@en
P2093
Barberin JM
Bourlière M
Boustière C
Guagliardo V
P2860
P356
10.1046/J.1365-2893.2002.00319.X
P577
2002-01-01T00:00:00Z